Anhydrous glucose

PreclinicalSmall molecule

TTanta University

Anhydrous glucose is one of 7 small molecule programs targeting Preoperative. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PreoperativeCompleted

PreoperativePreclinical

Completed

Competition

Competitive Landscape

10 competitors in Preoperative

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

3 2

Gleevec

Novartis

Phase 3

2 3

Flagyl

DDePuy Orthopaedics

Phase 2

2 4

Inderal

WWyeth-Lederle Vaccines

Phase 2

1 5

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 6

Zanaflex

LLegacy Health System

Preclinical

1 7

Anhydrous glucose

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Preoperative1 trial

Preoperative Two Hours Carbohydrate Load On Pediatric Patient Undergoing Elective Surgery

Completed·TTanta University·N/A·NCT06833671·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anhydrous glucose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anhydrous glucose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anhydrous glucose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tanta University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTanta University

Anhydrous glucose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Preoperative1 trial

References

Drug Info

Quick Facts

Related News